More research is needed about 6106-21-4

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 6106-21-4, SDS of cas: 6106-21-4.

In an article, author is Gentile, Salvatore, once mentioned the application of 6106-21-4, Name is Sodium succinate hexahydrate, molecular formula is C4H16Na2O10, molecular weight is 270.1434, MDL number is MFCD00149117, category is Benzisoxazole. Now introduce a scientific discovery about this category, SDS of cas: 6106-21-4.

A systematic review of quality of life and weight gain-related issues in patients treated for severe and persistent mental disorders: focus on aripiprazole

Aripiprazole is a relatively novel second-generation antipsychotic belonging to the chemical class of benzisoxazole derivatives and is characterized by a unique pharmacological profile which suggests that the drug acts as a dopamine-serotonin system stabilizer. Whereas all previously available antipsychotics are antagonists at D-2 receptors, aripiprazole is the only available partial agonist at these receptors. Thus, it has been suggested that aripiprazole could be associated with a relatively neutral impact on bodyweight, possibly reducing risks of a detrimental impact on the quality of life that often complicates management for a large number of patients diagnosed with severe and persistent mental disorders (SPMDs) treated chronically with antipsychotic medications. However, data from short- and long-term reviewed studies indicate that the prevalence rate of clinically relevant weight gain during therapy with this drug is similar to that occurring during treatments with other antipsychotic agents, either typical or atypical. Moreover, information on the impact of aripiprazole therapy on the quality of life of patients diagnosed with SPMDs is scarce and characterized by conflicting results. Given these results, further, large, well-designed studies are needed before confirming potential advantages of aripiprazole over first-generation antipsychotics and other SGAs.

Do you like my blog? If you like, you can also browse other articles about this kind. Thanks for taking the time to read the blog about 6106-21-4, SDS of cas: 6106-21-4.

Reference:
Benzisoxazole – Wikipedia,
,Benzisoxazole – an overview | ScienceDirect Topics